Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy

Breast

Volumn 23, Issue 1, 2014, Pages 44-49

  Rossi, Valentina ^a   Nolè, Franco ^b   Redana, Stefania ^a   Adamoli, Laura ^b   Martinello, Rossella ^a   Aurilio, Gaetano ^b   Verri, Elena ^b   Sapino, Anna ^c   Viale, Giuseppe ^d   Aglietta, Massimo ^d   Montemurro, Filippo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; De novo; HER2; Metastases; Recurring; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

BREAST CANCER; DE NOVO; HER2; METASTASES; RECURRING; TRASTUZUMAB;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84890871725     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.10.005     Document Type: Article

References (23)

1. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
2. Miller K.D., Sledge G.W. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 1999, 13:415-434.
3. Sant M., Allemani C., Berrino F., Coleman M.P., Aareleid T., Chaplain G., et al. Breast carcinoma survival in Europe and the United States. Cancer 2004, 100:715-722.
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
5. Dawood S., Broglio K., Ensor J., Hortobagyi G.N., Giordano S.H. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010, 21:2169-2174.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344:783-792.
7. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. JClin Oncol 2005, 23:4265-4274.
8. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. NEngl J Med 2006, 355:2733-2743.
9. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEngl J Med 2012, 367:1783-1791.
10. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366:109-119.
11. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
12. Ruiterkamp J., Voogd A.C., Bosscha K., Tjan-Heijnen V.C., Ernst M.F. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010, 120:9-16.
13. Petrelli F., Barni S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 2012, 29:3282-3290.
14. Babiera G.V., Rao R., Feng L., Meric-Bernstam F., Kuerer H.M., Singletary S.E., et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006, 13:776-782.
15. Bafford A.C., Burstein H.J., Barkley C.R., Smith B.L., Lipsitz S., Iglehart J.D., et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009, 115:7-12.
16. Rosche M., Regierer A.C., Schwarzlose-Schwarck S., Weigel A., Bangemann N., Schefe J.H., et al. Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature. Onkologie 2011, 34:607-612.
17. Cardoso F., Bedard P.L., Winer E.P., Pagani O., Senkus-Konefka E., Fallowfield L.J., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. JNatl Cancer Inst 2009, 101:1174-1181.
18. Rush Port E., Yeung H., Gonen M., Liberman L., Caravelli J., Borgen P., et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006, 13:677-684.
19. Klaeser B., Wiederkehr O., Koeberle D., Mueller A., Bubeck B., Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007, 18:1329-1334.
20. Groheux D., Hindie E., Delord M., Giacchetti S., Hamy A.S., de B.C., et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. JNatl Cancer Inst 2012, 104:1879-1887.
21. Giordano S.H., Buzdar A.U., Smith T.L., Kau S.W., Yang Y., Hortobagyi G.N. Is breast cancer survival improving?. Cancer 2004, 100:44-52.
22. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. JClin Oncol 2010, 28:92-98.
23. Andre F., Slimane K., Bachelot T., Dunant A., Namer M., Barrelier A., et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. JClin Oncol 2004, 22:3302-3308.